Study Effect of VIA-2291 on Vascular Inflammation

• Status: Completed
• Trial end date: 2008-09-01

Summary

This is a dose ranging study to compare the effect of VIA-2291 vs. Placebo on various inflammatory biomarkers in patients with recent acute coronary events

• Phase: Phase 2

Details

• Lead Sponsor: Tallikut Pharmaceuticals, Inc.
• Collaborator: Montreal Heart Institute
• Treatments: Atreleuton; Hydroxyurea